cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.15468/dl.v7w3rg
title: Occurrence Download

description: A dataset containing 66082 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is Colombia",
 "Geometry POLYGON((-180 -90,180 -90,180 90,-180 90,-180 -90))",
 {
 "or" : [
 "TaxonKey is Amazilia fimbriata nigricauda (D.G.Elliot, 1878)",
 "TaxonKey is Ara macao (Linnaeus, 1758)",
 "TaxonKey is Ara severus severus",
 "TaxonKey is Aratinga weddellii (Deville, 1851)",
 "TaxonKey is Attila cinnamomeus (Gmelin, 1789)",
 "TaxonKey is Chloroceryle amazona (Latham, 1790)",
 "TaxonKey is Columbina talpacoti eluta (Bangs, 1901)",
 "TaxonKey is Odontorchilus cinereus (Pelzeln, 1868)",
 "TaxonKey is Sicalis flaveola (Linnaeus, 1766)",
 "TaxonKey is Thraupis episcopus episcopus",
 "TaxonKey is Ficus rubiginosa Desf. ex Vent.",
 "TaxonKey is Catharanthus roseus (L.) G.Don",
 "TaxonKey is Celosia argentea L.",
 "TaxonKey is Echeveria secunda Booth ex Lindl.",
 "TaxonKey is Clidemia hirta Linnaeus, 1753",
 "TaxonKey is Cissus erosa (L.) Rich.",
 "TaxonKey is Solanum jamaicense Mill.",
 "TaxonKey is Siparuna guianensis Aubl.",
 "TaxonKey is Amaranthus hybridus L.",
 "TaxonKey is Lantana glandulosissima Hayek",
 "TaxonKey is Calycophyllum coccineum (Vahl) DC.",
 "TaxonKey is Piper hispidum Hayata",
 "TaxonKey is Phytolacca decandra L.",
 "TaxonKey is Plantago major var. leptostachya Wallr.",
 "TaxonKey is Psidium guajava L.",
 "TaxonKey is Sida rhombifolia L.",
 "TaxonKey is Paliurus spina-christi Mill.",
 "TaxonKey is Eriobotrya japonica (Thunb.) Lindl.",
 "TaxonKey is Alternanthera philoxeroides (Mart.) Griseb.",
 "TaxonKey is Impatiens parviflora DC.",
 "TaxonKey is Chrysanthemum coronarium L."
 ]
 }
 ]
}

 The dataset includes 66082 records from 274 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0215642-200613084148143/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.rv4wjf
title: Occurrence Download

description: A dataset containing 14043 species occurrences available in GBIF matching the query:
{
 "DatasetKey" : [
 "is Biodiverskripsi: Biodiversity Theses Database"
 ]
}

 The dataset includes 14043 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0074225-210914110416597/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.xv6fjq
title: Occurrence Download

description: A dataset containing 3601 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Phaneroptera nana Fieber, 1853"
 ]
}

 The dataset includes 3601 records from 97 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0020262-181108115102211/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.6m9az7
title: Occurrence Download

description: A dataset containing 215 species occurrences available in GBIF matching the query:
{
 "and" : [
 {
 "or" : [
 "BasisOfRecord is Human Observation",
 "BasisOfRecord is Specimen",
 "BasisOfRecord is Unknown evidence"
 ]
 },
 {
 "or" : [
 "DatasetKey is Grasshopper and Cricket (Orthoptera) and related species records from Britain and Ireland to 2007",
 "DatasetKey is SILENE-FAUNE-PACA - Parc_National_de_Port_Cros_2017_12_18",
 "DatasetKey is Atlas des Orthoptères et Mantides de France métropolitaine",
 "DatasetKey is iNaturalist Research-grade Observations",
 "DatasetKey is Welsh Invertebrate Database (WID)",
 "DatasetKey is Données d'occurrences Espèces issues de l'inventaire des ZNIEFF",
 "DatasetKey is SILENE-FAUNE-PACA - CEN_PACA_2017_12_18",
 "DatasetKey is Orthoptera and Allied Insects of the British Isles data from iRecord",
 "DatasetKey is Dorset SSSI Species Records 1952 - 2004 (Natural England)",
 "DatasetKey is Déterminations et observations du Forum \"Le Monde des Insectes\" (LMDI)-Données photographiques validées de la galerie du forum \"Le Monde des Insectes\""
 ]
 },
 "HasCoordinate is true",
 {
 "or" : [
 "Month is January",
 "Month is February",
 "Month is March",
 "Month is April",
 "Month is May",
 "Month is June",
 "Month is July",
 "Month is August",
 "Month is September",
 "Month is October",
 "Month is November",
 "Month is December"
 ]
 },
 "TaxonKey is Pseudomogoplistes Gorochov, 1984"
 ]
}

 The dataset includes 215 records from 10 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0153339-200613084148143/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.kzvxdo
title: Occurrence Download

description: A dataset containing 32843 species occurrences available in GBIF matching the query:
{
 "and" : [
 {
 "or" : [
 "TaxonKey is Sphagnum palustre L."
 ]
 },
 "HasCoordinate is true",
 "HasGeospatialIssue is false"
 ]
}

 The dataset includes 32843 records from 197 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0020263-180508205500799/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.25441631
title: Clinical validation of a fast-acting acetaminophen: a randomized, active and placebo controlled dental pain study

description: To address the need for faster pain relief of over-the-counter (OTC) analgesic users, a novel drug delivery technology was developed to achieve faster absorption of orally administered acetaminophen with the goal of delivering earlier onset of pain relief. Previous development studies suggested that a 1000 mg dose of this fast-acting acetaminophen (FA-acetaminophen) formulation provided faster absorption and onset of action versus, commercially available OTC fast-acting analgesics, 1000 mg of extra-strength acetaminophen (ES-acetaminophen) or 400 mg of liquid-filled ibuprofen capsules (LG-ibuprofen). This study was designed as the definitive trial evaluating the onset of pain relief of FA-acetaminophen versus these same OTC comparators. This single-dose, randomized, double-blind, placebo- and active-controlled clinical trial compared analgesic onset, overall efficacy, and safety of FA-acetaminophen 1000 mg, ES-acetaminophen 1000 mg, LG-ibuprofen 400 mg, and placebo over 4 h in a postsurgical dental pain model. Following removal of 3 to 4 impacted third molars, 664 subjects with moderate-to-severe pain were randomized in a 4:4:2:1 ratio to FA-acetaminophen (249), ES-acetaminophen (232), LG-ibuprofen (124), or placebo (59). Mean age was 18.9 years; 45.5% were male; 57.5% had severe baseline pain intensity. Subjects stopped a first stopwatch if/when they had perceptible pain relief and a second stopwatch if/when their pain relief became meaningful to them. Pain intensity difference (PID) and pain relief (PAR) were obtained using an 11-point numerical rating scale. FA-acetaminophen 1000 mg had faster median time to onset of pain relief (15.7 min) compared to ES-acetaminophen 1000 mg (20.2 min, <i>p</i> = 0.035), LG-ibuprofen 400 mg (23.2 min, <i>p</i> &lt; 0.001), and placebo (non-estimable), statistically greater mean PAR and PID scores than other treatment groups at 15 and 30 min, and a statistically greater percentage of subjects with confirmed perceptible pain relief at 15 and 20 min. At 25 min, FA-acetaminophen 1000 mg had a statistically significantly greater percentage of subjects with confirmed perceptible pain relief than LG-ibuprofen 400 mg and placebo. No clinically significant adverse events were reported. This study supports previous studies, demonstrating faster onset of analgesia with FA-acetaminophen 1000 mg compared to OTC ES-acetaminophen 1000 mg and OTC LG-ibuprofen 400 mg. NCT03224403 https://clinicaltrials.gov/ct2/show/NCT03224403
DOI: 10.6084/m9.figshare.25441631.v2
title: Clinical validation of a fast-acting acetaminophen: a randomized, active and placebo controlled dental pain study

description: To address the need for faster pain relief of over-the-counter (OTC) analgesic users, a novel drug delivery technology was developed to achieve faster absorption of orally administered acetaminophen with the goal of delivering earlier onset of pain relief. Previous development studies suggested that a 1000 mg dose of this fast-acting acetaminophen (FA-acetaminophen) formulation provided faster absorption and onset of action versus, commercially available OTC fast-acting analgesics, 1000 mg of extra-strength acetaminophen (ES-acetaminophen) or 400 mg of liquid-filled ibuprofen capsules (LG-ibuprofen). This study was designed as the definitive trial evaluating the onset of pain relief of FA-acetaminophen versus these same OTC comparators. This single-dose, randomized, double-blind, placebo- and active-controlled clinical trial compared analgesic onset, overall efficacy, and safety of FA-acetaminophen 1000 mg, ES-acetaminophen 1000 mg, LG-ibuprofen 400 mg, and placebo over 4 h in a postsurgical dental pain model. Following removal of 3 to 4 impacted third molars, 664 subjects with moderate-to-severe pain were randomized in a 4:4:2:1 ratio to FA-acetaminophen (249), ES-acetaminophen (232), LG-ibuprofen (124), or placebo (59). Mean age was 18.9 years; 45.5% were male; 57.5% had severe baseline pain intensity. Subjects stopped a first stopwatch if/when they had perceptible pain relief and a second stopwatch if/when their pain relief became meaningful to them. Pain intensity difference (PID) and pain relief (PAR) were obtained using an 11-point numerical rating scale. FA-acetaminophen 1000 mg had faster median time to onset of pain relief (15.7 min) compared to ES-acetaminophen 1000 mg (20.2 min, <i>p</i> = 0.035), LG-ibuprofen 400 mg (23.2 min, <i>p</i> &lt; 0.001), and placebo (non-estimable), statistically greater mean PAR and PID scores than other treatment groups at 15 and 30 min, and a statistically greater percentage of subjects with confirmed perceptible pain relief at 15 and 20 min. At 25 min, FA-acetaminophen 1000 mg had a statistically significantly greater percentage of subjects with confirmed perceptible pain relief than LG-ibuprofen 400 mg and placebo. No clinically significant adverse events were reported. This study supports previous studies, demonstrating faster onset of analgesia with FA-acetaminophen 1000 mg compared to OTC ES-acetaminophen 1000 mg and OTC LG-ibuprofen 400 mg. NCT03224403 https://clinicaltrials.gov/ct2/show/NCT03224403
DOI: 10.6084/m9.figshare.25620348
title: Diagnosis of bone marrow involvement in angioimmunoblastic T-cell lymphoma should be based on both [<sup>18</sup>F]FDG-PET/CT and bone marrow biopsy findings

description: During the initial staging of certain lymphoma subtypes, 18 F-fluorodeoxyglucose positron emission tomography/computed tomography ([<sup>18</sup>F]FDG-PET/CT) has become an alternative to bone marrow biopsy (BMB) for detecting bone marrow (BM) involvement. However, whether [<sup>18</sup>F]FDG-PET/CT can accurately detect BM involvement in angioimmunoblastic T-cell lymphoma (AITL) remains unknown. Our study aimed to assess the diagnostic and prognostic capability of [<sup>18</sup>F]FDG-PET/CT for detecting BM involvement in AITL. <b>Methods:</b> This retrospective study included 84 individuals newly diagnosed with AITL who underwent baseline BMB and [<sup>18</sup>F]FDG-PET/CT. “BM involvement” was defined as one or both of the following: 1) angioimmunoblastic T-cells detected in the BM; or 2) initially heightened focal uptake having disappeared on follow-up [<sup>18</sup>F]FDG-PET/CT. The ability of [<sup>18</sup>F]FDG-PET/CT to detect BM cancerous lesions was respectively analyzed by BM involvement confirmed by BMB or the aforementioned definition as the reference standard. The patients’ clinical characteristics and survival and prognostic outcomes were respectively analyzed. Of the 84 participants, five (6.0%) displayed positive BMB and PET/BM results, 17 (20.2%) had BMB-positive but PET/BM-negative results, eight (9.5%) showed BMB-negative but PET/BM-positive outcomes, and 54 (64.3%) displayed negative BMB and PET/BM outcomes. Using pre-defined BM involvement as the reference standard, [<sup>18</sup>F]FDG-PET/CT exhibited a specificity of 100%, sensitivity of 40%, negative predictive value (NPV) of 75%, and positive predictive value (PPV) of 100%. In contrast, using BMB-detected BM involvement as reference, [<sup>18</sup>F]FDG-PET/CT exhibited a sensitivity, specificity, PPV, and NPV of 38.5%, 76.1%, 22.7%, and 87.1%, respectively. Among patients with PET/BM-positive and BMB-negative outcomes, 62.5% (5/8) underwent upstaging from III to IV. In 58.8% (10/17) of patients who were initially diagnosed with stage II/III disease based on the [<sup>18</sup>F]FDG-PET/CT results, repeat BMB resulted in upstaging to IV. PET/BM-negative patients had a higher 3-year progression-free survival rate (38.3% vs. 22.8%, <i>p</i> = 0.018) and 3-year overall survival rate (64.4% vs. 34.6%, <i>p</i> = 0.011) than PET/BM-positive patients. In AITL patients, PET/BM-positive results may obviate the necessity for repeat BMB to ascertain confirm BM involvement. PET/BM-negative results do not definitively exclude BM involvement. The combined use of [<sup>18</sup>F]FDG-PET/CT and BMB can increase the diagnostic accuracy of BM involvement for AITL patients.
DOI: 10.6084/m9.figshare.25620348.v1
title: Diagnosis of bone marrow involvement in angioimmunoblastic T-cell lymphoma should be based on both [<sup>18</sup>F]FDG-PET/CT and bone marrow biopsy findings

description: During the initial staging of certain lymphoma subtypes, 18 F-fluorodeoxyglucose positron emission tomography/computed tomography ([<sup>18</sup>F]FDG-PET/CT) has become an alternative to bone marrow biopsy (BMB) for detecting bone marrow (BM) involvement. However, whether [<sup>18</sup>F]FDG-PET/CT can accurately detect BM involvement in angioimmunoblastic T-cell lymphoma (AITL) remains unknown. Our study aimed to assess the diagnostic and prognostic capability of [<sup>18</sup>F]FDG-PET/CT for detecting BM involvement in AITL. <b>Methods:</b> This retrospective study included 84 individuals newly diagnosed with AITL who underwent baseline BMB and [<sup>18</sup>F]FDG-PET/CT. “BM involvement” was defined as one or both of the following: 1) angioimmunoblastic T-cells detected in the BM; or 2) initially heightened focal uptake having disappeared on follow-up [<sup>18</sup>F]FDG-PET/CT. The ability of [<sup>18</sup>F]FDG-PET/CT to detect BM cancerous lesions was respectively analyzed by BM involvement confirmed by BMB or the aforementioned definition as the reference standard. The patients’ clinical characteristics and survival and prognostic outcomes were respectively analyzed. Of the 84 participants, five (6.0%) displayed positive BMB and PET/BM results, 17 (20.2%) had BMB-positive but PET/BM-negative results, eight (9.5%) showed BMB-negative but PET/BM-positive outcomes, and 54 (64.3%) displayed negative BMB and PET/BM outcomes. Using pre-defined BM involvement as the reference standard, [<sup>18</sup>F]FDG-PET/CT exhibited a specificity of 100%, sensitivity of 40%, negative predictive value (NPV) of 75%, and positive predictive value (PPV) of 100%. In contrast, using BMB-detected BM involvement as reference, [<sup>18</sup>F]FDG-PET/CT exhibited a sensitivity, specificity, PPV, and NPV of 38.5%, 76.1%, 22.7%, and 87.1%, respectively. Among patients with PET/BM-positive and BMB-negative outcomes, 62.5% (5/8) underwent upstaging from III to IV. In 58.8% (10/17) of patients who were initially diagnosed with stage II/III disease based on the [<sup>18</sup>F]FDG-PET/CT results, repeat BMB resulted in upstaging to IV. PET/BM-negative patients had a higher 3-year progression-free survival rate (38.3% vs. 22.8%, <i>p</i> = 0.018) and 3-year overall survival rate (64.4% vs. 34.6%, <i>p</i> = 0.011) than PET/BM-positive patients. In AITL patients, PET/BM-positive results may obviate the necessity for repeat BMB to ascertain confirm BM involvement. PET/BM-negative results do not definitively exclude BM involvement. The combined use of [<sup>18</sup>F]FDG-PET/CT and BMB can increase the diagnostic accuracy of BM involvement for AITL patients.
DOI: 10.15468/dl.cym3ya
title: Occurrence Download

description: A dataset containing 706 species occurrences available in GBIF matching the query:
{
 "and" : [
 "OccurrenceStatus is Present",
 {
 "or" : [
 "PublishingOrg is 85be57ed-f187-49c9-b7ff-eaa622e06217",
 "PublishingOrg is 2a7e3080-28a9-11dd-97cd-b8a03c50a862",
 "PublishingOrg is ccd1ddc0-6c21-11de-8224-b8a03c50a862",
 "PublishingOrg is eac88d99-9f6c-4031-8fc4-8088f0e0dfe7",
 "PublishingOrg is bc709e2f-6eb4-4cbe-a295-e12eed0679f2",
 "PublishingOrg is 0e2f2e28-7790-4c82-b8fb-6ef7b4c764e2",
 "PublishingOrg is 478a9e81-e716-42dc-a68d-03487953a32e",
 "PublishingOrg is 5a45153b-bdf9-44ae-b7a7-e3261896540b",
 "PublishingOrg is cccff716-2694-4209-9f9e-2f7a484465a0",
 "PublishingOrg is 493fe050-055d-11d8-b84f-b8a03c50a862"
 ]
 },
 {
 "or" : [
 "TaxonKey is Andinobates daleswansoni (Rueda-Almonacid, Rada, Sánchez-Pacheco, Velásquez-Álvarez & Quevedo-Gil, 2006)",
 "TaxonKey is Andinobates bombetes (Myers & Daly, 1980)",
 "TaxonKey is Andinobates dorisswansonae (Rueda-Almonacid, Rada, Sánchez-Pacheco, Velásquez-Álvarez & Quevedo-Gil, 2006)",
 "TaxonKey is Andinobates opisthomelas (Boulenger, 1899)",
 "TaxonKey is Andinobates tolimensis (Bernal-Bautista, Luna-Mora, Gallego & Quevedo-Gil, 2007)",
 "TaxonKey is Andinobates cassidyhornae Amézquita, Márquez, Mejía-Vargas, Kahn, Suárez & Mazariegos, 2013"
 ]
 }
 ]
}

 The dataset includes 706 records from 15 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0177877-200613084148143/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.25441631.v1
title: Clinical validation of a fast-acting acetaminophen: a randomized, active and placebo controlled dental pain study

description: <b>Objectives:</b> To address the need for faster pain relief of over-the-counter (OTC) analgesic users, a novel drug delivery technology was developed to achieve faster absorption of orally administered acetaminophen with the goal of delivering earlier onset of pain relief. Previous development studies suggested that a 1000 mg dose of this fast-acting acetaminophen (FA-acetaminophen) formulation provided faster absorption and onset of action versus, commercially available OTC fast-acting analgesics, 1000 mg of extra-strength acetaminophen (ES-acetaminophen) or 400 mg of liquid-filled ibuprofen capsules (LG-ibuprofen). This study was designed as the definitive trial evaluating the onset of pain relief of FA-acetaminophen versus these same OTC comparators. <b>Methods:</b> This single-dose, randomized, double-blind, placebo- and active-controlled clinical trial compared analgesic onset, overall efficacy, and safety of FA-acetaminophen 1000 mg, ES-acetaminophen 1000 mg, LG-ibuprofen 400 mg, and placebo over 4 hours in a postsurgical dental pain model. Following removal of 3 to 4 impacted third molars, 664 subjects with moderate-to-severe pain were randomized in a 4:4:2:1 ratio to FA-acetaminophen (249), ES-acetaminophen (232), LG-ibuprofen (124), or placebo (59). Mean age was 18.9 years; 45.5% were male; 57.5% had severe baseline pain intensity. Subjects stopped a first stopwatch if/when they had perceptible pain relief and a second stopwatch if/when their pain relief became meaningful to them. Pain intensity difference (PID) and pain relief (PAR) were obtained using an 11-point numerical rating scale. <b>Findings:</b> FA-acetaminophen 1000 mg had faster median time to onset of pain relief (15.7 minutes) compared to ES-acetaminophen 1000 mg (20.2 minutes, p = 0.035), LG-ibuprofen 400 mg (23.2 minutes, p &lt; 0.001), and placebo (non-estimable), statistically greater mean PAR and PID scores than other treatment groups at 15 and 30 minutes, and a statistically greater percentage of subjects with confirmed perceptible pain relief at 15 and 20 minutes. At 25 minutes, FA-acetaminophen 1000 mg had a statistically significantly greater percentage of subjects with confirmed perceptible pain relief than LG-ibuprofen 400 mg and placebo. No clinically significant adverse events were reported. <b>Conclusions:</b> This study supports previous studies, demonstrating faster onset of analgesia with FA-acetaminophen 1000 mg compared to OTC ES-acetaminophen 1000 mg and OTC LG-ibuprofen 400 mg. <b>ClinicalTrials.gov Identifier:</b> NCT03224403 https://clinicaltrials.gov/ct2/show/NCT03224403
DOI: 10.15468/dl.1m1gzx
title: Occurrence Download

description: A dataset containing 30542 species occurrences available in GBIF matching the query:
{
 "and" : [
 {
 "or" : [
 "TaxonKey is Sphagnum papillosum Lindb."
 ]
 },
 "HasCoordinate is true",
 "HasGeospatialIssue is false"
 ]
}

 The dataset includes 30542 records from 147 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0020264-180508205500799/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.hg8uft
title: Occurrence Download

description: A dataset containing 1 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Continent is South America",
 "Country is Colombia",
 "OccurrenceStatus is Present",
 "TaxonKey is Emerita portoricensis Schmitt, 1935"
 ]
}

 The dataset includes 1 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0048612-240506114902167/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.qj7s2b
title: Occurrence Download

description: A dataset containing 722 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Spiraea alba Du Roi",
 "BasisOfRecord is one of (Specimen)",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "Continent is North America"
 ]
}

 The dataset includes 722 records from 23 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0177915-200613084148143/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.fxg2ab
title: Occurrence Download

description: A dataset containing 407 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Houstonia caerulea L.",
 "BasisOfRecord is one of (Specimen)",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "Continent is North America"
 ]
}

 The dataset includes 407 records from 19 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0177948-200613084148143/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.jfjbqn
title: Occurrence Download

description: A dataset containing 1594 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Grus nigricollis Prjevalsky, 1876"
 ]
}

 The dataset includes 1594 records from 23 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0183271-200613084148143/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.m8bywz
title: Occurrence Download

description: A dataset containing 251744 species occurrences available in GBIF matching the query:
{
 "DatasetKey" : [
 "is Herbarium - Instituto Nacional de Pesquisas da Amazônia (INPA)"
 ]
}

 The dataset includes 251744 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0020264-190415153152247/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.